Extracellular proteasome in the alveolar space: characterisation and function under physiological and pathophysiological condition

Extracellular proteasome in the alveolar space: characterisation and function under physiological and pathophysiological condition: an observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN20709647

Enrollment

300

Registered

2007-10-19

Start date

2003-01-01

Completion date

Unknown

Last updated

2017-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracellular proteasome in the alveolar space Respiratory Characteristics of respiratory diseases

Interventions

Healthy caucasians subjects and patients with ARDS, sarcoidosis and patients after lung transplantation were included after approval of the local ethics committee and informed written consent. Observ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Acute respiratory distress syndrome: 1.1. Timing: acute onset 1.2. Oxygenation: Partial Pressure of Oxygen in Arterial Blood (PaO2)/Fraction of Inspired Oxygen (FiO2) ratio less than 200 mmHg (regardless of Positive End Expiratory Pressure [PEEP]) 1.3. Chest radiograph: bilateral infiltrates seen on frontal chest radiograph 1.4. Pulmonary Artery Wedge (PAW): less than 18 mmHg when measured or no clinical evidence of left atrial hypertension 2. Sarcoidosis 3. Lung transplantation: patient after lung transplantation were lavaged in a routine diagnostic, for the screening of organ rejection and infection 4. Aged 18 to 70 years, both genders

Exclusion criteria

Exclusion criteria: 1. Acute respiratory distress syndrome: contraindication against bronchoscopy 2. Sarcoidosis: contraindication against bronchoscopy 3. Lung transplantation: contraindication against bronchoscopy 4. Healthy subjects: 4.1. Contraindication against bronchoscopy 4.2. Any lung diseases 4.3. Infection 4.4. Sepsis 4.5. Coronary heart disease

Design outcomes

Primary

Measure	Time frame
1. Enzyme activity using specific proteasomal fluorogenic substrates and I125 albumin, with and without specific proteasome inhibitors 2. Detection of 20S proteasome with polyclonal antibody (western-blot) 3. Detection of immunoproteasome with LMP2 and LMP7 antibody (western-blot) 4. Gel filtration to evaluate the molecular weight of the extracellular proteasome in the bronchoalveolar space 5. Mass spectrometry of the gel filtration revealed hydrolysing activity and ELISA technique for the amount of extracellular, alveolar proteasome	—

Measure

Time frame

1. Enzyme activity using specific proteasomal fluorogenic substrates and I125 albumin, with and without specific proteasome inhibitors 2. Detection of 20S proteasome with polyclonal antibody (western-blot) 3. Detection of immunoproteasome with LMP2 and LMP7 antibody (western-blot) 4. Gel filtration to evaluate the molecular weight of the extracellular proteasome in the bronchoalveolar space 5. Mass spectrometry of the gel filtration revealed hydrolysing activity and ELISA technique for the amount of extracellular, alveolar proteasome

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026